TrialInvestigational new drugs2014

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.

A Necchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.